Sandoz
Sandoz opens biosimilar development centre in Slovenia
June 19, 2026Business Development Sandoz, biosimilar development
Sandoz has opened a new biosimilar development centre in Ljubljana, Slovenia, as part of efforts to expand its in-house capabilities …
Sandoz’ Ondibta receives European Commission approval for diabetes
January 26, 2026Research and Development Diabetes, Ondibta, Sandoz
Sandoz has announced that its Ondibta (insulin glargine) has received approval from the European Commission (EC) for the treatment of …
Sandoz launches two new bone disease biosimilars in Europe
December 3, 2025Sales and Marketing Oncology, Osteoporosis, Sandoz
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 mg) is approved for the …
Sandoz signs renewable energy deal to supply 90% of European operations
August 13, 2025Mergers and Acquisitions Corporate, Elawan Energy, Sandoz, decarbonisation, renewable energy
Sandoz has entered into a ten-year virtual Power Purchase Agreement with Elawan Energy for the development of new solar projects …
FDA approves Sandoz’s denosumab biosimilars
March 6, 2024Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab
Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …
Sandoz announces deal to commercialise biosimilar ustekinumab in Europe and North America
September 11, 2023Research and Development Pharmacy, SB17, Sandoz, commercialisation, ustekinumab
Sandoz has announced that it has entered into a development and commercialisation agreement with Samsung Bioepis, providing Sandoz the exclusive …
FDA approves Sandoz’s Tyruko biosimilar to treat relapsing forms of MS
August 25, 2023Medical Communications FDA, MS, Neurology, Sandoz
Novartis’ Sandoz has announced that the US Food and Drug Administration (FDA) has approved its biosimilar Tyruko (natalizumab-sztn), developed by …
Sandoz shares positive results from MYLIGHT phase 3 study
August 16, 2023Research and Development Opthalmology, Sandoz, aflibercept, clinical trial, wet macular degeneration
Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study for its biosimilar aflibercept, for …
NICE gives go-ahead for Sandoz’s Rizmoic to treat opioid-induced constipation
September 30, 2020Research and Development, Sales and Marketing NHS, NICE, Rizmoic, Sandoz, UK
The National Institute for Health and Care Excellence (NICE) has recommended Sandoz’s Rizmoic (naldemedine) for the treatment of opioid-induced constipation …
Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes
April 15, 2020Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma
Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …
Sandoz scores FDA approval for Neulasta biosimilar Ziextenzo to treat febrile neutropenia infection
November 6, 2019Research and Development, Sales and Marketing Amgen, FDA, Neulasta, Sandoz, Ziextenzo, pharma
The FDA has authorised the availability of Sandoz’s Ziextenzo (pegfilgrastim-bmez), a biosimilar version of Amgen’s Neulasta, it has emerged. The …
Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar
September 3, 2019Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma
Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …
Novartis aims to solve EpiPen shortage with generic launch of Symjepi to US pharmacies
July 10, 2019Manufacturing and Production, Research and Development, Sales and Marketing Mylan, Novartis, Sandoz, US, epipen, pharma
Novartis has announced the immediate availability of its generic epinephrine auto-injector in pharmacies throughout the US, as it moves to …
Top Ten most popular articles on Pharmafile.com this week
May 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten
On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …
Sandoz is first multinational to secure generic approval under new Chinese guidelines
May 20, 2019Sales and Marketing China, Novartis, Sandoz, generics, pharma, rosuvastatin
Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in …
